The effect of carbamoylpiperidine and nipecotoylpiperazine analogs on ADP-stimulated human thrombocyte aggregation and platelet factor 3 availability

Res Commun Chem Pathol Pharmacol. 1990 Feb;67(2):179-99.

Abstract

There is a striking congruence between the inhibitory effects of three synthetic entities on ADP-induced (i) human blood platelet aggregation and (ii) platelet factor 3 availability as evidenced by prolonged 'Stypven time'. The pronounced parallel between each compound's potency in inhibiting aggregation (e.g. IA 48.9 +/- 1.3, S.E., %; n = 16) and in impeding platelet factor 3 availability (e.g. IPF-3av 42.3 +/- 2.5, S.E., %; n = 12), determined concurrently in platelet-rich plasma of four different donors, further substantiates that the antiplatelet activity of our carbamoylpiperidine and nipecotoylpiperazine congeners is exerted through their interaction with anionic phospholipids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Diphosphate / physiology*
  • Adult
  • Animals
  • Blood Coagulation Factors / metabolism*
  • Humans
  • Male
  • Nipecotic Acids / metabolism
  • Nipecotic Acids / pharmacology*
  • Phosphatidylinositols / metabolism
  • Phosphatidylserines / metabolism
  • Piperazines*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Factor 3 / metabolism*

Substances

  • Blood Coagulation Factors
  • Nipecotic Acids
  • Phosphatidylinositols
  • Phosphatidylserines
  • Piperazines
  • Platelet Aggregation Inhibitors
  • alpha, alpha'-bis(3-(N,N-diethylcarbamoyl)piperidino)-4-xylene
  • Platelet Factor 3
  • Adenosine Diphosphate
  • 1,10-bis(3-(N,N-diethylcarbamoyl)piperidino)decane
  • N,N'-bis(1-decylnipecotoyl)piperazine